Biocryst Pharmaceuticals Stock Current Ratio

BCRX Stock

USD 7.69 0.17 2.16%

BioCryst Pharmaceuticals fundamentals help investors to digest information that contributes to BioCryst Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of BioCryst Stock. The fundamental analysis module provides a way to measure BioCryst Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioCryst Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	Current Ratio	2.63	2.50

Current Ratio is likely to drop to 2.50 in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BioCryst Pharmaceuticals Company Current Ratio Analysis

BioCryst Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current BioCryst Pharmaceuticals Current Ratio

5.19 X

Most of BioCryst Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioCryst Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

BioCryst Current Ratio Driver Correlations

Understanding the fundamental principles of building solid financial models for BioCryst Pharmaceuticals is extremely important. It helps to project a fair market value of BioCryst Stock properly, considering its historical fundamentals such as Current Ratio. Since BioCryst Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioCryst Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioCryst Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Short Term Investments	Common Stock	Current Deferred Revenue	Property Plant Equipment	Net Receivables	Net Tangible Assets	Long Term Debt	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.59	0.42	-0.94	0.78	0.95	0.99	-0.69	0.67	0.93	-0.31	0.88	0.77	-0.81	0.93	0.93	0.87	-0.66	-0.17	0.16	0.94	0.95	0.94
Total Stockholder Equity	-0.59		-0.22	0.47	-0.7	-0.37	-0.61	0.09	0.01	-0.59	0.42	-0.46	-0.09	0.21	-0.32	-0.43	-0.68	0.55	0.08	-0.09	-0.59	-0.62	-0.47
Net Debt	0.42	-0.22		-0.39	0.4	0.44	0.45	-0.42	0.49	0.3	-0.08	0.34	0.28	-0.57	0.48	0.3	0.35	-0.18	-0.22	-0.25	0.48	0.51	0.37
Retained Earnings	-0.94	0.47	-0.39		-0.67	-0.96	-0.92	0.58	-0.83	-0.97	0.41	-0.9	-0.83	0.82	-0.93	-0.91	-0.87	0.67	0.21	-0.32	-0.8	-0.82	-0.94
Accounts Payable	0.78	-0.7	0.4	-0.67		0.62	0.82	-0.35	0.28	0.77	-0.33	0.6	0.33	-0.43	0.57	0.67	0.82	-0.55	-0.31	0.06	0.78	0.82	0.75
Total Liab	0.95	-0.37	0.44	-0.96	0.62		0.94	-0.77	0.83	0.9	-0.24	0.88	0.9	-0.92	0.99	0.95	0.79	-0.57	-0.23	0.18	0.87	0.88	0.94
Total Current Assets	0.99	-0.61	0.45	-0.92	0.82	0.94		-0.69	0.64	0.93	-0.28	0.85	0.74	-0.81	0.91	0.94	0.87	-0.66	-0.25	0.14	0.96	0.97	0.94
Short Term Debt	-0.69	0.09	-0.42	0.58	-0.35	-0.77	-0.69		-0.58	-0.5	-0.36	-0.66	-0.81	0.85	-0.82	-0.74	-0.45	0.21	0.19	0.12	-0.77	-0.75	-0.67
Short Term Investments	0.67	0.01	0.49	-0.83	0.28	0.83	0.64	-0.58		0.71	-0.18	0.75	0.84	-0.79	0.83	0.7	0.57	-0.45	-0.11	0.28	0.5	0.51	0.72
Common Stock	0.93	-0.59	0.3	-0.97	0.77	0.9	0.93	-0.5	0.71		-0.4	0.87	0.75	-0.69	0.85	0.9	0.91	-0.75	-0.24	0.39	0.79	0.82	0.95
Current Deferred Revenue	-0.31	0.42	-0.08	0.41	-0.33	-0.24	-0.28	-0.36	-0.18	-0.4		-0.2	0.04	0.11	-0.17	-0.17	-0.34	0.32	-0.02	-0.13	-0.18	-0.19	-0.22
Property Plant Equipment	0.88	-0.46	0.34	-0.9	0.6	0.88	0.85	-0.66	0.75	0.87	-0.2		0.81	-0.76	0.87	0.83	0.81	-0.54	-0.11	0.33	0.76	0.77	0.82
Net Receivables	0.77	-0.09	0.28	-0.83	0.33	0.9	0.74	-0.81	0.84	0.75	0.04	0.81		-0.88	0.92	0.84	0.61	-0.44	-0.17	0.33	0.67	0.67	0.83
Net Tangible Assets	-0.81	0.21	-0.57	0.82	-0.43	-0.92	-0.81	0.85	-0.79	-0.69	0.11	-0.76	-0.88		-0.96	-0.83	-0.59	0.34	0.26	-0.02	-0.82	-0.8	-0.8
Long Term Debt	0.93	-0.32	0.48	-0.93	0.57	0.99	0.91	-0.82	0.83	0.85	-0.17	0.87	0.92	-0.96		0.93	0.74	-0.52	-0.24	0.15	0.87	0.87	0.91
Long Term Debt Total	0.93	-0.43	0.3	-0.91	0.67	0.95	0.94	-0.74	0.7	0.9	-0.17	0.83	0.84	-0.83	0.93		0.79	-0.58	-0.38	0.18	0.88	0.89	0.96
Capital Surpluse	0.87	-0.68	0.35	-0.87	0.82	0.79	0.87	-0.45	0.57	0.91	-0.34	0.81	0.61	-0.59	0.74	0.79		-0.74	-0.15	0.31	0.77	0.8	0.88
Deferred Long Term Liab	-0.66	0.55	-0.18	0.67	-0.55	-0.57	-0.66	0.21	-0.45	-0.75	0.32	-0.54	-0.44	0.34	-0.52	-0.58	-0.74		0.09	-0.59	-0.51	-0.55	-0.64
Long Term Investments	-0.17	0.08	-0.22	0.21	-0.31	-0.23	-0.25	0.19	-0.11	-0.24	-0.02	-0.11	-0.17	0.26	-0.24	-0.38	-0.15	0.09		-0.06	-0.25	-0.29	-0.35
Short Long Term Debt	0.16	-0.09	-0.25	-0.32	0.06	0.18	0.14	0.12	0.28	0.39	-0.13	0.33	0.33	-0.02	0.15	0.18	0.31	-0.59	-0.06		-0.08	-0.04	0.25
Net Invested Capital	0.94	-0.59	0.48	-0.8	0.78	0.87	0.96	-0.77	0.5	0.79	-0.18	0.76	0.67	-0.82	0.87	0.88	0.77	-0.51	-0.25	-0.08		0.99	0.86
Net Working Capital	0.95	-0.62	0.51	-0.82	0.82	0.88	0.97	-0.75	0.51	0.82	-0.19	0.77	0.67	-0.8	0.87	0.89	0.8	-0.55	-0.29	-0.04	0.99		0.88
Capital Stock	0.94	-0.47	0.37	-0.94	0.75	0.94	0.94	-0.67	0.72	0.95	-0.22	0.82	0.83	-0.8	0.91	0.96	0.88	-0.64	-0.35	0.25	0.86	0.88

Click cells to compare fundamentals

BioCryst Current Ratio Historical Pattern

Today, most investors in BioCryst Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioCryst Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of BioCryst Pharmaceuticals current ratio as a starting point in their analysis.

BioCryst Pharmaceuticals Current Ratio

Timeline

Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).

Competition

Predict BioCryst Pharmaceuticals

Current Ratio Over Time

BioCryst Price To Sales Ratio

Price To Sales Ratio

3.28

At this time, BioCryst Pharmaceuticals' Price To Sales Ratio is fairly stable compared to the past year.

In accordance with the recently published financial statements, BioCryst Pharmaceuticals has a Current Ratio of 5.19 times. This is 78.35% higher than that of the Biotechnology sector and 25.86% lower than that of the Health Care industry. The current ratio for all United States stocks is 140.28% lower than that of the firm.

BioCryst Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioCryst Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioCryst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics of similar companies.

BioCryst Pharmaceuticals is currently under evaluation in current ratio category among its peers.

BioCryst Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BioCryst Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BioCryst Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

BioCryst Fundamentals

	Return On Equity	-19.25
	Return On Asset	-0.0016
	Profit Margin	(0.20) %
	Operating Margin	(0.03) %
	Current Valuation	2.09 B
	Shares Outstanding	208.96 M
	Shares Owned By Insiders	1.45 %
	Shares Owned By Institutions	81.01 %
	Number Of Shares Shorted	16.68 M
	Price To Earning	(7.11) X
	Price To Book	56.59 X
	Price To Sales	3.57 X
	Revenue	450.71 M
	Gross Profit	264.79 M
	EBITDA	12.81 M
	Net Income	(88.88 M)
	Cash And Equivalents	417.48 M
	Cash Per Share	2.24 X
	Total Debt	12.82 M
	Debt To Equity	2.40 %
	Current Ratio	5.19 X
	Book Value Per Share	(2.28) X
	Cash Flow From Operations	(52.02 M)
	Short Ratio	6.16 X
	Earnings Per Share	(0.43) X
	Price To Earnings To Growth	(0.28) X
	Target Price	14.73
	Number Of Employees	580
	Beta	1.85
	Market Capitalization	1.61 B
	Total Asset	490.42 M
	Retained Earnings	(1.77 B)
	Working Capital	261.58 M
	Current Asset	65.99 M
	Current Liabilities	64.45 M
	Net Asset	490.42 M

About BioCryst Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BioCryst Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
CRM	Salesforce
CRM	Salesforce

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC